Abstract:Introduction Human rhinoviruses (RV) are one of the main aetiological agents responsible for respiratory tract infections. RVs are divided into three species termed Rhinovirus A, B and C with over 150 types identified within these species. There has been growing evidence of RV infections causing severe respiratory illness in vulnerable populations such as infants with underlying respiratory or immunocompromised conditions. Aims and objectives We aimed to evaluate molecular epidemiology and associated clinical severity of Rhino virus infections retrospectively in hospitalised children aged < than 2 years. Materials and methods Nasopharyngeal and respiratory secretions from hospitalised children who tested positive for Rhino virus were included. The only exclusion factor was children with cystic fibrosis. We analysed rhino virus subtypes and its clinical association on samples obtained during the study period from January 2014 until August 2014. In total 100 clinical samples met the criteria which was then subtyped. Viral subtyping was performed by nucleic acid extraction, amplification and sequencing of the 5’ non-coding region (NCR) of the viral genome. Information on demographics, antecedent respiratory conditions and risk factors (immune suppression), clinical presentation and progress (oxygen and ventilation requirements) were collected. Additional data collected includes presence or absence of viral respiratory co infections, bacterial infections and antibiotic treatment. Results The distribution of RV species, subtyped by sequencing regions of the 5’NCR observed in this study were; 57 RV-A, two RV-B and 29 RV-C. The data generated in this study provided some suggestive evidence of RV-C infection being associated with more severe acute respiratory symptoms and that RV-A infection although more prevalent commonly results in fever and is associated with extended patient length of stay in hospital. The 5’NCR sequencing assay utilised in this study was able to subtype 91% of clinical samples within a diagnostic laboratory setting using only clinical sample nucleic acid extracts. Conclusion The knowledge of sub type in infants and young children would be quite useful to predict the disease severity and clinical course especially in vulnerable population. Also it does illustrate the importance of prevention of nosocomial Rhinovirus infections in the interest of avoiding excessive bed-days.

Pre-clinical development of a novel cross-protective rhinovirus vaccine.

Immunogenicity and protective efficacy of an RSV G S177Q central conserved domain nanoparticle vaccine

RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models

Induction of neutralising antibodies against conserved rhinovirus capsid protein VP4 depends on presenting VP4 in a virus-like conformation

G524(P) The molecular epidemiology and clinical disease severity of Human Rhino virus infections in hospitalised children

Non-invasive epicutaneous vaccine against Respiratory Syncytial Virus: Preclinical proof of concept

Pre-Clinical Development of an Adenovirus Vector Based RSV and Shingles Vaccine Candidate

Evaluation of the protective potential of antibody and T cell responses elicited by a novel preventative vaccine towards respiratory syncytial virus small hydrophobic protein

Misdirected antibody responses against an N-terminal epitope on human rhinovirus VP1 as explanation for recurrent RV infections

Strategic priorities for respiratory syncytial virus (RSV) vaccine development

A Safe and Effective Mucosal RSV Vaccine Consisting of RSV Phosphoprotein and Flagellin Variant

Combinatorial F-G Immunogens as Nipah and Respiratory Syncytial Virus Vaccine Candidates

Mucosal Application of a Low-Energy Electron Inactivated Respiratory Syncytial Virus Vaccine Shows Protective Efficacy in an Animal Model

Development of a respiratory syncytial virus vaccine using human hepatitis B core-based virus-like particles to induce mucosal immunity

OM-85s anti-rhinovirus response assessed on human primary nasal epithelial cells

Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine

Safety, immunogenicity, and protective efficacy of a recombinant vaccine against RSV: Evidence from murine and bovine models

A Pan-Pneumovirus vaccine based on immunodominant epitopes of the fusion protein

Epicutaneous immunization using synthetic virus-like particles efficiently boosts protective immunity to respiratory syncytial virus

Experimental trials of predicted CD4+ and CD8+ T-cell epitopes of respiratory syncytial virus

Design and Preclinical Evaluation of a Nanoparticle Vaccine against Respiratory Syncytial Virus Based on the Attachment Protein G